What patent coverage (or exclusivity) exists for esterified estrogens formulations from Monarch Pharmaceuticals and Pfizer?
Public information on exact patent numbers or exclusivity terms depends on the specific product and application (for example, whether the discussion is about the NDA/ANDA holder, a branded product name, or a particular “esterified estrogens” strength). With only the question provided, I cannot reliably identify which specific patents or regulatory exclusivities you mean for Monarch Pharmaceuticals and Pfizer without the product name and jurisdiction.
Which specific product should I match to the right patents?
“Esterified estrogens” are sold under different brand names and sometimes in different regulatory jurisdictions. To map “formulation” patents to Monarch and Pfizer, you typically need at least one of the following:
- Product name/brand name (and strength)
- Dosage form (tablet, delayed release, etc.)
- Country/region (U.S., EU, UK, etc.)
- Approval type (NDA vs ANDA) and the reference listed drug (RLD), if in the U.S.
If you share the product name(s), I can narrow to the correct patent family(ies) and the related regulatory exclusivity listings.
Where do the key U.S. “formulation” rights usually show up?
If you are asking about U.S. rights, “formulation” protection typically comes from a mix of:
- Listed patents tied to the approved drug in the Orange Book (often including composition/formulation claims, not just method-of-use)
- Regulatory exclusivities (for example, exclusivity tied to the application rather than to a specific formulation patent), such as:
- 5-year exclusivity (new chemical entity or other application-based exclusivity scenarios)
- 3-year exclusivity (new clinical investigations that support approval, where applicable)
- Pediatric exclusivity extensions (if granted)
- Any market exclusivity tied to the regulatory pathway used
But the actual details (numbers, expiration dates, which patents cover which claim scope) must be taken from the Orange Book and the associated patent documents for the specific product.
Why Monarch vs Pfizer might have different “exclusivity details”
Different companies can appear in different roles:
- One company may hold the approved reference product.
- Another may hold a formulation patent (assigned/licensed) or be associated with an ANDA applicant/labeling.
- Ownership of patents can change over time via assignments, and Orange Book listings can differ from patent ownership recorded in USPTO records.
So “Monarch Pharmaceuticals and Pfizer” could refer to:
- A specific patent owned by one, while the NDA is held by the other, or
- A dispute/litigation settlement where patent listing and exclusivity are discussed publicly.
What I need from you to produce the exact patent/exclusivity details you’re asking for
Please provide at least one of these so I can give a precise, citation-backed answer:
1) The exact product name(s) for “esterified estrogens” you mean, and the country (U.S. vs EU, etc.), or
2) The relevant NDA number(s) (U.S.) or marketing authorization numbers (EU), or
3) A link or the Orange Book entry you’re looking at, or
4) The specific Monarch and Pfizer assets you mean (e.g., “Monarch’s ANDA product vs Pfizer’s reference listed drug”).
Once you provide that, I can list the publicly available patents (by number and claim type where relevant) and any applicable regulatory exclusivity/expiration dates tied to the formulation.
Sources
No sources were cited because no specific product/patent/exclusivity records were identifiable from the prompt alone.